பூமா நோயாளி லின்க்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பூமா நோயாளி லின்க்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பூமா நோயாளி லின்க்ஸ் Today - Breaking & Trending Today

CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration


Press release content from Business Wire. The AP news staff was not involved in its creation.
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration
February 25, 2021 GMT
BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 25, 2021
CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing drug candidates in China and North Asia, and Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, have agreed to terminate their 2018 license agreement, in which Puma granted CANbridge exclusive rights to develop and commercialize NERLYNX® (neratinib) in Greater China, and to settle their arbitration related to the license agreement. ....

United States , Hong Kong , Pierre Fabre , James Xue , Puma Biotechnology Inc , Umass Medical School , Horae Gene Therapy Center , Canbridge Pharmaceuticals Inc , Planet Communications , North Asia , Puma Biotechnology , Greater China , Middle East , Positive Breast , Wuxi Biologics , Medical School , Pharmaceuticals Inc , Fetal Toxicity , Full Prescribing Information , Puma Patient Lynx , Business Wire , Products And Services , Diagnosis And Treatment , Licensing Agreements , Pharmaceutical Manufacturing , Health Care Industry ,

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the


Search jobs
11-Dec-2020
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer
LOS ANGELES, Calif., December 11, 2020 / B3C newswire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial,” is being presented at a Spotlight Poster Discussion Session by Frankie Ann Holmes, M.D., FACP, Texas Oncology Houston – US Oncolog ....

United States , Frankie Ann Holmes , Maggie Beller , Alanh Auerbach , Puma Biotechnology Inc , European Union , European Commission , Drug Administration , Us Oncology Research , Puma Biotechnology , San Antonio Breast Cancer Symposium , Spotlight Poster Discussion Session , Texas Oncology Houston , Clinical Breast , Chief Executive Officer , Control Poster , Positive Breast , Fetal Toxicity , Full Prescribing Information , Puma Patient Lynx , Breast Neoplasms , Clinical Trials , Survival Analysis , Disease Free Survival , Neoadjuvant Therapy , ஒன்றுபட்டது மாநிலங்களில் ,